1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,910 | 1,946 | 12:01 | |
| 1,906 | 1,950 | 12:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:00 | SynAct Pharma AB: SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil - term sheet signed | 61 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the company has signed... ► Artikel lesen | |
| 05.08. | SynAct Pharma AB: SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation | 497 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has issued a favorable Decision on Appeal in... ► Artikel lesen | |
| 20.07. | SynAct Pharma AB: SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness | 668 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct" or the "Company") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company developing resolution therapies for inflammatory diseases, today announced that it has... ► Artikel lesen | |
| 29.06. | SynAct Pharma AB: BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study | 754 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through resolution therapy, today provides an update following... ► Artikel lesen | |
| SYNACT PHARMA Aktie jetzt für 0€ handeln | |||||
| 15.06. | SynAct Pharma AB: Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering | 446 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, reported today that resomelagon in combination... ► Artikel lesen | |
| 12.06. | SynAct Pharma AB: SynAct obtains key US patent for resomelagon securing exclusivity until 2044 | 578 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") announced today that the United States Patent and Trademark Office (USPTO) have provided the issue notification of US patent 12,661,336 with issue date 23 June 2026... ► Artikel lesen | |
| 11.06. | SynAct Pharma AB: Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ) | 419 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) held its Annual General Meeting today, Thursday 11 June 2026, at the offices of MAQS Advokatbyrå in Stockholm. Attorney Eric Ehrencrona from MAQS Advokatbyrå was elected as chairman... ► Artikel lesen | |
| 27.05. | SynAct Pharma AB: SynAct Pharma publishes Q1 2026 interim results | 353 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the first quarter 2026.
"As we close the first quarter of 2026, SynAct Pharma is in a stronger position than at any previous... ► Artikel lesen | |
| 06.05. | SynAct Pharma AB: SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study | 597 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully completed dosing... ► Artikel lesen | |
| 26.03. | SynAct Pharma AB: SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon | 271 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the first patients were dosed... ► Artikel lesen | |
| 03.03. | SynAct Pharma - Multiple shots on goal in 2026 for resomelagon | 533 | Edison Investment Research | SynAct Pharma's FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment... ► Artikel lesen | |
| 24.02. | SynAct Pharma AB: SynAct Pharma appoints Ann Kristin Led as Chief Financial Officer | 252 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Ann Kristin... ► Artikel lesen | |
| 18.02. | SynAct Pharma AB: SynAct Pharma Year-end Report 2025 | 289 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced its Year-end Report 2025
"As we close the fourth quarter and conclude 2025, I am pleased with the steady progress SynAct Pharma has made across clinical... ► Artikel lesen | |
| 10.02. | SynAct Pharma - Resomelagon progresses in RA, viral infections | 551 | Edison Investment Research | SynAct Pharma has completed patient recruitment for its Phase IIb ADVANCE trial (n=240) in rheumatoid arthritis (RA), while initiating the Phase II RESPIRE study in hospitalised with respiratory insufficiency... ► Artikel lesen | |
| 06.02. | SynAct Pharma AB: SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study | 500 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully reached the recruitment... ► Artikel lesen | |
| 30.01. | SynAct Pharma AB: SynAct Pharma initiates Phase 2 study in respiratory insufficiency | 444 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it has initiated... ► Artikel lesen | |
| 19.01. | SynAct Pharma AB: SynAct Pharma appoints Malin Wikstrand as interim CFO | 255 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announces that Malin Wikstrand... ► Artikel lesen | |
| 27.11.25 | SynAct Pharma AB: Report from the Extraordinary General Meeting of SynAct Pharma AB | 307 | GlobeNewswire (Europe) | An Extraordinary General Meeting in SynAct Pharma AB (publ) was held today, 27 November 2025, at MAQS Advokatbyrå's premises at Stureplan 19 in Stockholm. Chairperson of the General Meeting was Matilda... ► Artikel lesen | |
| 03.11.25 | SynAct Pharma AB: Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion | 374 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has randomized 190 out of 240 patients... ► Artikel lesen | |
| 31.10.25 | SynAct Pharma - Approaching a catalyst-rich period | 442 | Edison Investment Research | SynAct Pharma's Q325 results underscored the company's steady progress on its clinical strategy, led by the ongoing Phase IIb ADVANCE trial evaluating resomelagon as a first-line treatment for rheumatoid... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,690 | -0,10 % | Hitze, Dürre und Wassermangel Ein Sektor-Kaufsignal für Umwelt-Experten wie Bayer, MustGrow, Kraft Heinz und Unilever | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die verheerende Kombination aus anhaltender Dürre, akutem Wassermangel und extremer Hitze stellt die globale Wirtschaft und die weltweite... ► Artikel lesen | |
| ABBVIE | 223,80 | +0,04 % | Im Windschatten von Eli Lilly und Novo Nordisk: AbbVie und Gubra vor dem nächsten großen Schritt | Der dänische Wirkstoffforscher Gubra agiert am Puls der Zeit. Das Unternehmen treibt eine relativ frühe Entwicklungspipeline mit einem Fokus auf Adipositas-Wirkstoffe voran. Das verpartnerte Projekt... ► Artikel lesen | |
| ELI LILLY | 1.053,00 | -0,62 % | Novo Nordisk gegen Eli Lilly, Johnson & Johnson setzt auf Zelltherapie - wo entsteht der nächste Milliardenmarkt? | ||
| MERCK & CO | 116,46 | -0,29 % | Merck & Co. Aktienanalyse: Patentschutz bröckelt, neue Rekorde sind dennoch möglich! | Die amerikanische Merck & Co. (ISIN: US58933Y1055) gehört zu den größten Pharmakonzernen der Welt und steht wie kaum ein anderes Unternehmen für die Erfolgsgeschichte der modernen Immunonkologie. Mit... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 57,38 | +0,53 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| INNOCAN PHARMA | 1,390 | +0,72 % | Achtung: InnoCan Pharma droht Absturz trotz starker Aktionärsbewertungen | ||
| DOCMORRIS | 9,710 | -4,71 % | DocMorris hebt die Prognose kräftig an - warum die Aktie trotzdem verliert | DocMorris liefert starke Halbjahreszahlen und wird für 2026 deutlich optimistischer. Vor allem das Geschäft mit rezeptpflichtigen Medikamenten gewinnt massiv an Fahrt, gleichzeitig rückt die operative... ► Artikel lesen | |
| INCYTE | 105,95 | -0,66 % | Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? | ||
| SINOPHARM | 1,860 | -0,46 % | SINOPHARM (01099): ANNOUNCEMENT PRINCIPAL UNAUDITED FINANCIAL DATA OF CNMDC FOR THE SIX MONTHS ENDED 30 JUNE 2026 | ||
| HAPPY BELLY FOOD GROUP | 0,980 | +1,55 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Rosie's Burgers Announces the Grand Opening of its Newest Location in Montreal's Griffintown | Montreal, Quebec--(Newsfile Corp. - August 14, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("HappyBelly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| COMPASS PATHWAYS | 11,900 | -1,65 % | Vergiss Zulassungen! Wer zahlt für die Therapie? Diese 3 Biotech-Aktien zeigen, worauf es jetzt wirklich ankommt | ||
| HIGH TIDE | 2,040 | -1,21 % | High Tide Inc.: High Tide Announces Voting Results of Annual General and Special Meeting of Shareholders | CALGARY, AB, Aug. 12, 2026 /PRNewswire/ -- High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 248,00 | -0,80 % | Stifel reiterates Buy on Ligand Pharma stock, $332 target | ||
| JAZZ PHARMACEUTICALS | 217,30 | -0,69 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio | Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy
Leverages Jazz development expertise and commercial strength in... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 11,400 | +0,88 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen |
Das Unternehmen SYNACT PHARMA AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,920 Euro und damit +7,38 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNACT PHARMA AB finden Sie auf Wallstreet Online.